Adrenal Cortical Hyperfunction: Endocrine Excess

Adrenal cortical hyperfunction represents a complex spectrum of endocrinopathies characterized by the autonomous or dysregulated hypersecretion of steroid hormones from the cortex of the adrenal glands. Because these adrenal steroids—encompassing glucocorticoids, mineralocorticoids, and adrenal androgens—modulate everything from cellular metabolism and systemic vascular tone to immune surveillance and secondary sexual characteristics, unmitigated secretory excess invariably triggers widespread multisystem morbidity. Deciphering the pathophysiological mechanisms, diagnostic pathways, and therapeutic interventions for adrenocortical overactivity remains one of the most intellectually demanding and clinically consequential domains in modern endocrinology.

Adrenal Cortical Hyperfunction

1. Concise Definition

Adrenal cortical hyperfunction denotes a pathological condition wherein one or more layers of the adrenal cortex synthesize and release excessive quantities of steroid hormones into systemic circulation, independent of or disproportionate to normal physiological feedback mechanisms. This hypersecretory state primarily manifests as Cushing’s syndrome due to glucocorticoid overproduction, primary aldosteronism via mineralocorticoid excess, or virilizing/feminizing syndromes mediated by adrenal sex steroids.

At its biochemical foundation, the condition arises when the tightly regulated homeostatic loops of the hypothalamic-pituitary-adrenal (HPA) axis or the renin-angiotensin-aldosterone system (RAAS) fail. Such dysregulation can stem from primary adrenocortical neoplasia, bilateral adrenocortical hyperplasia, aberrant receptor expression, or downstream germline and somatic mutations that perpetuate steroidogenesis without trophic hormone stimulation.

The systemic manifestations of adrenocortical hyperfunction are profoundly debilitating. Unchecked hormone levels systematically disrupt intermediary metabolism, induce vascular remodeling, exacerbate psychiatric symptoms, and compromise skeletal integrity, rendering rapid identification and targeted clinical management vital.

2. Etymology & Linguistic Origin

The terminology underlying adrenal cortical hyperfunction is rooted in classical Latin and Greek medical nomenclature. The component adrenal derives from the Latin prefix ad- (meaning “near” or “at”) and the substantive noun renes (referring to the kidneys), denoting the anatomical location of these bilateral glands atop the renal poles. The word cortical stems from the Latin cortex, translating literally to “bark,” “rind,” or outer anatomical shell, distinguishing the outer steroid-producing layers from the inner neuroectodermal medulla.

The prefix hyper- originates from the Ancient Greek ὑπέρ (hypér), denoting “over,” “beyond,” or “excessive.” Finally, function is inherited from the Latin functio (from fungi, meaning “to perform” or “to execute”). Historically, the term coalesced across early-to-mid 20th-century endocrinological literature as clinical investigators began separating primary glandular hypersecretion from pituitary-driven hyperactivity, progressively standardizing the phrase to classify steroidogenic overproduction originating within the adrenal cortex itself.

3. Pronunciation & Grammatical Form

Pronunciation: /əˈdriː.nəl ˈkɔːr.tɪ.kəl ˌhaɪ.pərˈfʌŋk.ʃən/

Grammatical Class: Compound nominal phrase (noun).

Syntactic Variations & Usage: The phrase functions as an overarching clinical category. In academic literature, it frequently appears in adjectival modifications such as “adrenocortical hyperfunctional states” or nominal variants like “hyperfunctioning adrenocortical adenoma.” The term contrasts directly with “adrenocortical hypofunction” (primary adrenal insufficiency or Addisonian states) and is clinically segregated from medullary hyperfunction (such as pheochromocytoma).

4. Detailed Conceptual Explanation

The adrenal cortex is organized into three distinct histological zones, each responsible for producing specific classes of steroid hormones derived from cholesterol. The outermost layer, the zona glomerulosa, expresses aldosterone synthase (CYP11B2) to produce the mineralocorticoid aldosterone. The middle and largest layer, the zona fasciculata, expresses 11β-hydroxylase (CYP11B1) and 17α-hydroxylase (CYP17A1) to synthesize glucocorticoids, predominantly cortisol. The innermost layer, the zona reticularis, collaborates in generating adrenal androgens, including dehydroepiandrosterone (DHEA), its sulfate ester (DHEA-S), and androstenedione.

Adrenal cortical hyperfunction develops when cellular proliferation or biochemical hyperactivity within one or more of these zones escapes physiological suppressive cues. In the zona fasciculata, autonomous hypersecretion of cortisol saturates the capacity of corticosteroid-binding globulin (CBG), precipitating an exponential rise in biologically active free cortisol. Circulating cortisol binds with high affinity to ubiquitous intracellular glucocorticoid receptors (GR), altering gene transcription across virtually all tissues. This leads to profound protein catabolism, accelerated hepatic gluconeogenesis, secondary insulin resistance, redistribution of adipose stores to central depots, and suppression of cellular immunity.

When hyperfunction localizes to the zona glomerulosa, autonomous aldosterone production occurs independent of renin or angiotensin II signaling. Aldosterone binds selectively to cytosolic mineralocorticoid receptors (MR) in the renal distal convoluted tubule and cortical collecting duct. This engagement upregulates the expression and membrane trafficking of epithelial sodium channels (ENaC) and basolateral Na+/K+-ATPase pumps. Consequently, the kidney accelerates sodium resorption in exchange for potassium and hydrogen ion excretion, yielding intravascular hypervolemia, suppressed plasma renin activity, systemic arterial hypertension, hypokalemia, and metabolic alkalosis.

In hyperfunctional states involving the zona reticularis or undifferentiated adrenocortical carcinoma, mass production of adrenal androgens occurs. In biological females and prepubertal children, excessive DHEA and androstenedione undergo peripheral conversion into potent androgens such as testosterone and dihydrotestosterone (DHT). This induces rapid virilization, hirsutism, clitoromegaly, severe cystic acne, and disruption of the hypothalamic-pituitary-gonadal axis, leading to oligomenorrhea or amenorrhea.

5. Historical Development

The understanding of adrenal cortical hyperfunction evolved over more than a century of clinical observation, biochemical discovery, and molecular genetics:

• Early Clinical Identification: In 1912, American neurosurgeon Harvey Cushing described a distinctive clinical syndrome marked by central adiposity, cutaneous striae, osteoporosis, and hypertension, which he initially attributed to basophil adenomas of the pituitary gland. Subsequent investigators discovered that an identical phenotype could arise from primary adrenal neoplasms operating independently of the pituitary.
• Isolation of Cortical Hormones: During the 1930s and 1940s, Edward C. Kendall, Tadeus Reichstein, and Philip S. Hench successfully isolated and characterized adrenal corticosteroids, demonstrating their anti-inflammatory and metabolic properties—an accomplishment recognized with the 1950 Nobel Prize in Physiology or Medicine.
• Recognition of Primary Aldosteronism: In 1954, Jerome W. Conn documented the clinical picture of severe arterial hypertension associated with hypokalemia and suppressed renin, identifying a discrete, aldosterone-producing adrenocortical adenoma—a condition subsequently memorialized as Conn’s syndrome.
• Molecular and Genetic Revolution: The late 20th and early 21st centuries clarified the genetic mutations underlying adrenal autonomy. The discovery of somatic mutations in potassium channels (KCNJ5) in aldosterone-producing adenomas, alongside mutations in the catalytic subunit of protein kinase A (PRKACA) and the tumor suppressor ARMC5 in cortisol-secreting micronodular and macronodular hyperplasia, transformed adrenocortical hyperfunction from a descriptive clinical syndrome into a precisely classified molecular disorder.

6. Theoretical Foundations

The clinical and physiological evaluation of adrenocortical hyperfunction relies on classical homeostatic feedback theory and cellular signal transduction paradigms. Under normal conditions, the hypothalamic-pituitary-adrenocortical (HPA) axis operates through a closed, negative feedback loop. Hypothalamic corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) stimulate the anterior pituitary to secrete adrenocorticotropic hormone (ACTH). ACTH binds to melanocortin type 2 receptors (MC2R) on adrenocortical cells, activating adenylyl cyclase, elevating cyclic AMP (cAMP), and promoting steroidogenesis.

In primary adrenal hypercortisolism, this negative feedback loop is uncoupled. Autonomous production of cortisol by an adrenocortical neoplasm or hyperplastic tissue exerts continuous negative feedback at the hypothalamic and pituitary levels, suppressing endogenous CRH and ACTH release. The absence of circulating ACTH leads to atrophy of normal, non-tumorous adrenocortical tissue in both the ipsilateral and contralateral glands.

A parallel homeostatic framework governs mineralocorticoid secretion via the renin-angiotensin-aldosterone system. Normally, renal hypoperfusion or hyponatremia triggers renin release from the juxtaglomerular apparatus, converting angiotensinogen to angiotensin I, which is cleaved by angiotensin-converting enzyme (ACE) to angiotensin II. Angiotensin II subsequently stimulates aldosterone synthase in the zona glomerulosa. In autonomous mineralocorticoid hyperfunction, aldosterone secretion proceeds entirely unbound from angiotensin II stimulation. The resulting plasma volume expansion and renal baroreceptor activation shut down juxtaglomerular renin production, creating the classic hallmark of primary aldosteronism: elevated aldosterone alongside deeply suppressed plasma renin.

7. Key Components, Types & Dimensions

Adrenal cortical hyperfunction encompasses several clinical and biochemical subtypes based on the dominant hormone secreted, the underlying histological lesion, and its regulatory independence:

• Hypercortisolism (Endogenous Cushing’s Syndrome): Overproduction of cortisol can be categorized by ACTH dependency:
  • ACTH-Independent Cortical Hyperfunction: Driven directly by adrenal pathology, including solitary unilateral adrenocortical adenomas (accounting for approximately 60% of ACTH-independent cases), adrenocortical carcinomas, primary pigmented nodular adrenocortical disease (PPNAD, often linked to Carney complex), and bilateral macronodular adrenal hyperplasia (BMAH).
  • Mild Autonomous Cortisol Secretion (MACS): Subclinical hypercortisolism frequently discovered incidentally during abdominal imaging for unrelated reasons, marked by incomplete HPA axis suppression without the classic physical signs of Cushing’s syndrome.
• Primary Aldosteronism (Mineralocorticoid Excess): Characterized by autonomous, non-suppressible aldosterone synthesis, presenting primarily as:
  • Aldosterone-Producing Adenoma (APA / Conn’s Syndrome): A solitary, benign unilateral tumor that accounts for roughly 30–40% of primary aldosteronism cases.
  • Bilateral Idiopathic Hyperaldosteronism (IHA): Diffuse micronodular or macronodular hyperplasia of both adrenal cortices, representing approximately 60% of cases.
  • Familial Hyperaldosteronism (Types I–IV): Rare monogenic forms, such as glucocorticoid-remediable aldosteronism (GRA/FH-I), caused by an unequal crossover between the CYP11B1 and CYP11B2 genes.
• Adrenocortical Hyperandrogenism: The isolated or concurrent excess of adrenal androgens (DHEA, DHEA-S, androstenedione). While classic Congenital Adrenal Hyperplasia (CAH) represents enzyme deficiency with secondary ACTH-driven cortical hyperplasia, autonomous and unsuppressed androgen hyperfunction is most commonly pathognomonic of malignant adrenocortical carcinoma.
• Mixed Functional Syndromes: Highly aggressive adrenocortical carcinomas that concurrently co-secrete multiple steroid intermediates, such as cortisol alongside androgens or mineralocorticoids, yielding rapid-onset, multisystem clinical deterioration.

8. Examples & Illustrative Cases

Case Illustration 1: ACTH-Independent Cortisol-Secreting Adenoma
A 42-year-old female presents with progressive proximal muscle weakness, central weight gain, facial rounding (“moon facies”), supraclavicular fat pad accumulation, and wide violaceous abdominal striae. Over six months, she developed secondary type 2 diabetes and treatment-resistant hypertension. Laboratory testing reveals elevated 24-hour urinary free cortisol and a non-suppressed midnight salivary cortisol. Her 8:00 AM plasma ACTH is undetectable (< 5 pg/mL), confirming an ACTH-independent etiology. Contrast-enhanced abdominal computed tomography (CT) identifies a 3.4 cm well-circumscribed, lipid-rich left adrenal nodule with contralateral adrenal atrophy. Laparoscopic left adrenalectomy yields complete biochemical remission, requiring temporary perioperative and postoperative hydrocortisone replacement until her suppressed contralateral gland recovers.

Case Illustration 2: Aldosterone-Producing Adenoma (Conn’s Syndrome)
A 36-year-old male with persistent hypertension despite adhering to a three-drug antihypertensive regimen experiences muscle cramps and episodic paresthesias. Routine serum panels demonstrate marked hypokalemia (serum potassium: 2.8 mmol/L) accompanied by metabolic alkalosis. Screening tests reveal a significantly elevated plasma aldosterone concentration (PAC) alongside suppressed plasma renin activity (PRA), producing an aldosterone-to-renin ratio (ARR) exceeding 40. Confirmation with an intravenous saline suppression test demonstrates a failure of aldosterone levels to fall below physiological thresholds. Subsequent adrenal venous sampling (AVS) documents lateralization of aldosterone hypersecretion to the right adrenal gland. Following right-sided adrenalectomy, his serum potassium normalizes without oral supplementation, and his blood pressure resolves to normotensive ranges without medication.

9. Measurement & Assessment

Diagnosing adrenal cortical hyperfunction requires a systematic, step-wise approach combining screening, confirmatory biochemical testing, and high-resolution anatomical and functional imaging:

• Biochemical Screening for Glucocorticoid Excess: Initial guidelines require at least two concordant positive screening tests:
  • Overnight 1-mg Dexamethasone Suppression Test (DST): Serum cortisol measured at 8:00 AM following oral administration of 1 mg dexamethasone at 11:00 PM; values > 1.8 µg/dL (50 nmol/L) suggest autonomous cortisol secretion.
  • 24-Hour Urinary Free Cortisol (UFC): Direct quantification of unbound cortisol excreted over 24 hours, with values exceeding three times the upper limit of normal confirming hypercortisolemia.
  • Late-Night Salivary Cortisol (LNSC): Evaluates the loss of the normal physiological circadian nadir; elevated late-night salivary levels provide a sensitive, non-invasive biomarker.
• Biochemical Screening for Mineralocorticoid Excess:
  • Aldosterone-to-Renin Ratio (ARR): The primary screening tool for primary aldosteronism, pairing elevated plasma aldosterone with suppressed plasma renin activity or direct active renin concentration.
  • Confirmatory Suppression Tests: Oral sodium loading tests, intravenous saline infusion tests, or fludrocortisone suppression tests used to prove that aldosterone output cannot be suppressed by volume expansion.
• Etiological Discrimination & Adonal Mapping:
  • Plasma ACTH Quantification: Undetectable or suppressed baseline plasma ACTH confirms primary adrenal hypercortisolism, distinguishing it from pituitary Cushing’s disease or ectopic ACTH secretion.
  • Adrenal-Protocol Computed Tomography / MRI: High-resolution cross-sectional imaging to distinguish benign adenomas (characterized by high unenhanced intracellular lipid content, < 10 Hounsfield Units, and rapid contrast washout) from adrenocortical carcinomas (heterogeneous, large, calcified, slow washout).
  • Adrenal Venous Sampling (AVS): The gold standard for distinguishing unilateral adenomas amenable to curative surgical resection from bilateral adrenal hyperplasia requiring lifelong mineralocorticoid receptor antagonist pharmacotherapy.

10. Applications & Practical Significance

Accurate clinical identification of adrenal cortical hyperfunction directly influences long-term cardiovascular, metabolic, and psychiatric prognosis. Left untreated, chronic hypercortisolemia accelerates atherosclerotic vascular disease, increases the risk of fatal thromboembolism, induces osteoporosis with spontaneous vertebral collapse, and causes severe neuropsychiatric disturbances ranging from cognitive impairment to steroid psychosis.

Prompt recognition of primary aldosteronism is similarly critical. Mineralocorticoid hyperfunction exerts toxic, pro-fibrotic effects on the myocardium, systemic vasculature, and renal parenchyma that extend far beyond elevated blood pressure alone. Patients with primary aldosteronism suffer higher rates of stroke, myocardial infarction, left ventricular hypertrophy, and end-stage renal disease than age- and blood-pressure-matched controls with essential hypertension.

From an interventional perspective, determining whether hyperfunction is unilateral or bilateral dictates management. Unilateral lesions can often be cured via minimally invasive laparoscopic or robotic adrenalectomy, resolving or substantially ameliorating hypertension and metabolic derangements. Conversely, bilateral hyperfunctional disease requires targeted long-term pharmacotherapy, using mineralocorticoid receptor antagonists (such as spironolactone or eplerenone) or adrenal steroidogenesis inhibitors (such as metyrapone, ketoconazole, or osilodrostat).

11. Research & Empirical Evidence

Over the past two decades, high-throughput genomic and transcriptomic investigations have illuminated the pathophysiology of adrenocortical autonomous states. Seminal studies by Lifton and colleagues (Choi et al., 2011) identified somatic gain-of-function mutations in the KCNJ5 gene, which encodes the inward-rectifier potassium channel Kir3.4. These mutations disrupt channel selectivity, allowing continuous sodium influx, cellular depolarization, activation of voltage-gated calcium channels, and constitutive calcium-dependent transcription of the aldosterone synthase gene (CYP11B2).

Similarly, landmark investigations into cortisol-producing adenomas by Beuschlein et al. (2014) and Cao et al. (2014) identified recurrent somatic mutations in the PRKACA gene, which encodes the catalytic subunit alpha of protein kinase A. The specific Leu206Arg mutation disrupts the regulatory-catalytic subunit binding interface, leaving the kinase constitutively active and driving autonomous cortisol synthesis independent of ACTH receptor activation.

Regarding clinical outcomes, large-scale registry trials, including data from the European Network for the Study of Adrenal Tumors (ENSAT), have established that even “mild autonomous cortisol secretion” (MACS) found in adrenal incidentalomas increases all-cause mortality, cardiovascular events, and osteoporotic fractures. This evidence has shifted international clinical paradigms toward more aggressive screening and personalized treatment for subclinical disease.

12. Cultural & Cross-Cultural Considerations

The presentation, diagnosis, and management of adrenal cortical hyperfunction vary considerably across healthcare systems and geographic populations. In resource-rich regions, the widespread use of cross-sectional abdominal imaging has led to high detection rates of “adrenal incidentalomas” (encountered in up to 4–7% of routine abdominal CT scans), revealing large cohorts of patients with subclinical hypercortisolism or primary aldosteronism who would have otherwise remained undiagnosed.

In contrast, in low-resource environments with limited access to advanced biochemical assays and imaging, adrenal cortical hyperfunction is rarely detected until patients present with severe, end-stage manifestations such as refractory hypokalemic paralysis, necrotizing opportunistic infections secondary to steroid-induced immunosuppression, or advanced metastatic adrenocortical carcinoma.

Dietary habits also significantly influence diagnostic accuracy across cultures. Diets with high sodium consumption mask the hypokalemia typically associated with primary aldosteronism, whereas low-sodium diets can elevate baseline plasma renin levels, complicating ARR interpretations. Furthermore, the cultural use of herbal medicines containing licorice (which contains glycyrrhizinic acid, an inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 2) frequently mimics primary mineralocorticoid hyperfunction by allowing normal circulating cortisol to act directly on renal mineralocorticoid receptors—a condition termed apparent mineralocorticoid excess (AME).

13. Criticisms, Debates & Limitations

Despite robust diagnostic algorithms, substantial debate surrounds the screening and management thresholds for adrenocortical hyperfunction:

• The Primary Aldosteronism Screening Paradox: Epidemiological data suggest that primary aldosteronism accounts for 5% to 10% of all hypertensive patients and up to 20% of treatment-resistant cases. Despite this high prevalence, fewer than 2% of eligible hypertensive patients undergo formal ARR screening worldwide, reflecting an ongoing disconnect between clinical practice guidelines and primary care practice.
• The Subclinical Hypercortisolism Threshold: Considerable controversy persists regarding the diagnostic criteria for Mild Autonomous Cortisol Secretion (MACS). While a post-dexamethasone cortisol level > 1.8 µg/dL is widely accepted as an indicator of autonomous production, clinical consensus remains divided on whether asymptomatic patients within the 1.9–5.0 µg/dL range should undergo surgical adrenalectomy or conservative medical management.
• Technical Challenges of Adrenal Venous Sampling (AVS): Although AVS remains the gold standard for distinguishing unilateral from bilateral primary aldosteronism, it requires specialized interventional radiological expertise. Cannulating the small, acute-angled right adrenal vein carries high failure rates, and centers vary significantly regarding continuous cosyntropin (ACTH) infusion protocols and diagnostic cutoffs for lateralization indices.

14. Related Terms & Distinctions

Accurate diagnosis requires distinguishing adrenal cortical hyperfunction from related pathophysiological entities:

• Adrenal Medullary Hyperfunction (Pheochromocytoma): Arises from chromaffin cells of the adrenal medulla and secretes catecholamines (epinephrine, norepinephrine), whereas cortical hyperfunction exclusively involves steroid hormones (cortisol, aldosterone, androgens).
• Adrenal Cortical Hypofunction (Addison’s Disease): Characterized by the destruction or failure of the adrenal cortex, resulting in life-threatening mineralocorticoid and glucocorticoid deficiencies—the physiological opposite of cortical hyperfunction.
• Secondary Adrenocortical Hyperfunction: Glandular overactivity driven by external trophic stimulation—such as an ACTH-secreting pituitary corticotroph adenoma (Cushing’s disease) or renal artery stenosis driving hyperreninemic hyperaldosteronism—rather than intrinsic adrenal pathology.
• Exogenous Cushing’s Syndrome: Glucocorticoid excess resulting from pharmacologic steroid administration, distinguished biologically by bilateral adrenal cortical atrophy due to prolonged suppression of endogenous ACTH.

15. Summary / Key Takeaways

Adrenal cortical hyperfunction encompasses an array of endocrine disorders defined by the uninhibited overproduction of adrenal steroid hormones. Its primary clinical presentations—hypercortisolism, primary aldosteronism, and adrenal virilization—arise from neoplastic transformations or hyperplastic remodelling across the functional zones of the adrenal cortex. Clinicians establish diagnosis via structured biochemical screening, functional suppression and confirmation testing, and cross-sectional imaging, supplemented by adrenal venous sampling for subtype differentiation.

Surgical adrenalectomy offers a definitive cure for unilateral adenomas, whereas bilateral hyperplasia requires lifelong targeted medical therapy. Early recognition and definitive management remain essential to halt and reverse the substantial cardiovascular, metabolic, musculoskeletal, and psychiatric damage caused by chronic steroid hormone excess.

References

• Beuschlein, F., Fassnacht, M., Assié, G., Calebiro, D., Stratakis, C. A., Osswald, A., Ronchi, C. L., Wieland, T., Sbiera, S., Faucz, F. R., Schaak, K., Schmittfull, A., Schwarzmayr, T., Barreau, O., Vezzosi, D., Rizk-Rabin, M., Zabel, U., Szarek, E., Salpea, P., … Bertherat, J. (2014). Constitutive activation of PKA catalytic subunit in adrenal Cushing’s syndrome. New England Journal of Medicine, 370(11), 1019–1028. https://doi.org/10.1056/NEJMoa1310359
• Choi, M., Scholl, U. I., Yue, P., Björklund, P., Zhao, B., Nelson-Williams, C., Ji, W., Cho, Y., Patel, A., Men, C. J., Lolis, E., Wisgerhof, M. V., Geller, D. S., Lifton, R. P., & Wang, W. (2011). K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science, 331(6018), 768–772. https://doi.org/10.1126/science.1198785
• Fassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., Tabarin, A., Terzolo, M., Tsagarakis, S., & Dekkers, O. M. (2016). Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. European Journal of Endocrinology, 175(2), G1–G34. https://doi.org/10.1530/EJE-16-0467
• Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., Stowasser, M., & Young, W. F. (2016). The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 101(5), 1889–1916. https://doi.org/10.1210/jc.2015-4061
• Nieman, L. K., Biller, B. M., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008). The diagnosis of Cushing’s syndrome: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 93(5), 1526–1540. https://doi.org/10.1210/jc.2008-0125